Vitae Pharmaceuticals, Inc. Announces Promising Data for VTP-4, Drug Candidate Advancing Toward Clinical Testing for the Treatment of Atherosclerosis

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Vitae Pharmaceuticals, a clinical-stage biopharmaceutical company discovering and developing novel, small molecule, best-in-class compounds, today announced the presentation of promising preclinical in vivo data for the Company’s Liver X Receptor (LXR) modulator, VTP-4, being studied for the treatment of atherosclerosis. VTP-4 is a potent and selective modulator of LXRß, activation of which has been shown to stimulate reverse cholesterol transport (RCT), to decrease vascular inflammation and to provide protection in several in vivo models of atherosclerosis.